表紙
市場調査レポート

筋痙縮:世界の治験動向

Muscle Spasticity Global Clinical Trials Review, H2, 2016

発行 GlobalData 商品コード 308782
出版日 ページ情報 英文 189 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
筋痙縮:世界の治験動向 Muscle Spasticity Global Clinical Trials Review, H2, 2016
出版日: 2016年07月27日 ページ情報: 英文 189 Pages
概要

当レポートでは、筋痙縮治療薬に関する治験の最新動向について分析しており、G7 (主要7カ国) 諸国およびE7 (新興7カ国) における治験件数、被験者数、有望なスポンサー、治験に携わっている主な企業や機関、有望な薬剤の情報をまとめています。

当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の主要5ヶ国における治験件数
    • 欧州の主要5ヶ国における治験件数
    • 北米の主要国における治験件数
    • 中東・アフリカの主要国における治験件数
    • 中南米の主要国における治験件数

G7諸国での治験件数:中枢神経系疾患治療薬の治験における筋痙縮の割合

G7諸国における段階別の治験件数

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:中枢神経系疾患治療薬の治験における筋痙縮の割合

E7諸国における段階別の治験件数

E7諸国での治験件数:進捗状況別

段階別の治験件数

  • 進行中の治験:段階別

進捗状況別の治験件数

治験の目標の達成状況

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

筋痙縮治療薬の治験に携わっている主要企業

有望な薬剤

最新の治験ニュース

治験プロファイルの概要

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC3550CTIDB

GlobalData's clinical trial report, "Muscle Spasticity Global Clinical Trials Review, H2, 2016" provides an overview of Muscle Spasticity clinical trials scenario. This report provides top line data relating to the clinical trials on Muscle Spasticity. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Muscle Spasticity to Central Nervous System Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Muscle Spasticity to Central Nervous System Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Muscle Spasticity Therapeutics Clinical Trials
  • Prominent Drugs
    • Latest Clinical Trials News on Muscle Spasticity
      • May 25, 2016: Flex Pharma Initiates Human Efficacy Study with Single Molecule Tablet in Nocturnal Leg Cramps
      • Apr 19, 2016: Flex Pharma's Positive Human NLC Study Selected for Presentation at AAN Annual Meeting
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
      • Definitions
      • Research Methodology
      • Secondary Research
      • About GlobalData
      • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Muscle Spasticity Therapeutics, Global, Clinical Trials by Region, 2016*
  • Muscle Spasticity Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Muscle Spasticity Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Muscle Spasticity Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016*
  • Muscle Spasticity Therapeutics Clinical Trials, Europe, Top Five Countries, 2016*
  • Muscle Spasticity Therapeutics Clinical Trials, North America, Top Countries, 2016*
  • Muscle Spasticity Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016*
  • Muscle Spasticity Therapeutics Clinical Trials, Central and South America, Top Countries, 2016*
  • Proportion of Muscle Spasticity to Central Nervous System Clinical Trials, G7 Countries (%), 2016*
  • Muscle Spasticity Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Muscle Spasticity Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Muscle Spasticity to Central Nervous System Clinical Trials, E7 Countries (%), 2016*
  • Muscle Spasticity Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Muscle Spasticity Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Muscle Spasticity Therapeutics, Global, Clinical Trials by Phase, 2016*
  • Muscle Spasticity Therapeutics, Global, Clinical Trials In Progress by Phase 2016*
  • Muscle Spasticity Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Muscle Spasticity Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Muscle Spasticity Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Muscle Spasticity Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016*
  • Muscle Spasticity Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Muscle Spasticity Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Muscle Spasticity Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*

List of Figures

  • Muscle Spasticity Therapeutics, Global, Clinical Trials by Region (%), 2016*
  • Muscle Spasticity Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Muscle Spasticity Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Muscle Spasticity Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016*
  • Muscle Spasticity Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016*
  • Muscle Spasticity Therapeutics Clinical Trials, North America, Top Countries (%), 2016*
  • Muscle Spasticity Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016*
  • Muscle Spasticity Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016*
  • Proportion of Muscle Spasticity to Central Nervous System Clinical Trials, G7 Countries (%), 2016*
  • Muscle Spasticity Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Muscle Spasticity Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Muscle Spasticity to Central Nervous System Clinical Trials, E7 Countries (%), 2016*
  • Muscle Spasticity Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Muscle Spasticity Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Muscle Spasticity Therapeutics, Global, Clinical Trials by Phase (%), 2016*
  • Muscle Spasticity Therapeutics, Global, Clinical Trials In Progress by Phase, 2016*
  • Muscle Spasticity Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Muscle Spasticity Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Muscle Spasticity Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Muscle Spasticity Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016*
  • Muscle Spasticity Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Muscle Spasticity Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Muscle Spasticity Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*
  • GlobalData Methodology
Back to Top